homovanillic acid has been researched along with Parkinsonian Disorders in 64 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral administration of 10% solution of Phytomix-40 (multicomponent plant phytoadaptogen) to C57Bl/6 mice with MPTP-induced Parkinson's syndrome alleviated symptoms (oligokinesia and muscle rigidity), compensated for the deficiency of dopamine and its metabolites (DOPAC and homovanillic acid), and reduced the level of lipid peroxides in the striatum." | 3.73 | Effect of complex phytoadaptogen on MPTP-induced Parkinson's syndrome in mice. ( Belorustseva, SA; Bocharov, EV; Bocharova, OA; Kryzhanovskii, GN; Kucheryanu, VG; Kudrin, VS, 2006) |
| "In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and α-lipoic acid (C/LA nanomicellar complex) was demonstrated." | 1.48 | Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. ( Berezhnoy, DS; Fedorova, TN; Kulikova, OI; Lopachev, AV; Orlova, VS; Stvolinsky, SL, 2018) |
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| " Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i." | 1.40 | Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014) |
| "Layered hydroxide nanoparticles are generally biocompatible, and less toxic than most inorganic nanoparticles, making them an acceptable alternative drug delivery system." | 1.40 | Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model. ( Ain, NM; Fakurazi, S; Hussein, MZ; Hussein-Al-Ali, SH; Kura, AU, 2014) |
| " Therefore, the aim of the present study was to examine whether the long-term administration of a commonly used herbicide, paraquat, which has already been found to induce a slowly progressing degeneration of the nigrostriatal neurons, influences mesocortical dopaminergic neurons in rats." | 1.33 | Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. ( Biedka, I; Bortel, A; Dabrowska, J; Kuter, K; Nowak, P; Ossowska, K; Rommelspacher, H; Schulze, G; Smiałowska, M; Wardas, J; Wierońska, J; Zieba, B, 2006) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.32 | Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. ( Di Monte, DA; Langston, JW; Thiffault, C, 2003) |
| " In addition, chronic GDNF treatment did not induce the side-effects generally associated with chronic administration of levodopa, the most widely used treatment for Parkinson's disease." | 1.31 | Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. ( Andersen, AH; Cass, WA; Elsberry, DD; Gash, DM; Gerhardt, GA; Grondin, R; Klein, MC; Maswood, N; Yi, A; Zhang, Z, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.56) | 18.2507 |
| 2000's | 43 (67.19) | 29.6817 |
| 2010's | 19 (29.69) | 24.3611 |
| 2020's | 1 (1.56) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, R | 1 |
| Kurihara, M | 1 |
| Kameyama, M | 1 |
| Komatsu, H | 1 |
| Higashino, M | 1 |
| Hatano, K | 1 |
| Ihara, R | 1 |
| Higashihara, M | 1 |
| Nishina, Y | 1 |
| Matsubara, T | 1 |
| Kanemaru, K | 1 |
| Saito, Y | 1 |
| Murayama, S | 1 |
| Iwata, A | 1 |
| Celorrio, M | 1 |
| Rojo-Bustamante, E | 1 |
| Fernández-Suárez, D | 1 |
| Sáez, E | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Müller, CE | 1 |
| Ramírez, MJ | 1 |
| Oyarzábal, J | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Kulikova, OI | 1 |
| Berezhnoy, DS | 1 |
| Stvolinsky, SL | 1 |
| Lopachev, AV | 1 |
| Orlova, VS | 1 |
| Fedorova, TN | 1 |
| Noelker, C | 2 |
| Morel, L | 1 |
| Lescot, T | 1 |
| Osterloh, A | 1 |
| Alvarez-Fischer, D | 2 |
| Breloer, M | 1 |
| Henze, C | 1 |
| Depboylu, C | 1 |
| Skrzydelski, D | 1 |
| Michel, PP | 1 |
| Dodel, RC | 2 |
| Lu, L | 1 |
| Hirsch, EC | 3 |
| Hunot, S | 1 |
| Hartmann, A | 1 |
| Stuckenholz, V | 1 |
| Bacher, M | 1 |
| Balzer-Geldsetzer, M | 1 |
| Oertel, WH | 1 |
| Gruden, MA | 1 |
| Davydova, TV | 1 |
| Narkevich, VB | 1 |
| Fomina, VG | 1 |
| Wang, C | 1 |
| Kudrin, VS | 2 |
| Morozova-Roche, LA | 1 |
| Sewell, RD | 1 |
| Oeckl, P | 1 |
| Scheffold, A | 1 |
| Lechel, A | 1 |
| Rudolph, KL | 1 |
| Ferger, B | 3 |
| Kura, AU | 1 |
| Ain, NM | 1 |
| Hussein, MZ | 1 |
| Fakurazi, S | 1 |
| Hussein-Al-Ali, SH | 1 |
| Morin, N | 1 |
| Morissette, M | 1 |
| Grégoire, L | 1 |
| Di Paolo, T | 1 |
| Konieczny, J | 2 |
| Czarnecka, A | 2 |
| Kamińska, K | 1 |
| Lenda, T | 2 |
| Nowak, P | 2 |
| Humphreys, P | 1 |
| Barrowman, N | 1 |
| Ip, CW | 1 |
| Klaus, LC | 1 |
| Karikari, AA | 1 |
| Visanji, NP | 1 |
| Brotchie, JM | 2 |
| Lang, AE | 1 |
| Volkmann, J | 1 |
| Koprich, JB | 1 |
| Boulet, S | 1 |
| Mounayar, S | 1 |
| Poupard, A | 1 |
| Bertrand, A | 1 |
| Jan, C | 1 |
| Pessiglione, M | 1 |
| Feuerstein, C | 1 |
| François, C | 1 |
| Féger, J | 1 |
| Savasta, M | 1 |
| Tremblay, L | 1 |
| Viaggi, C | 1 |
| Vaglini, F | 1 |
| Pardini, C | 1 |
| Caramelli, A | 1 |
| Corsini, GU | 1 |
| Cheng, B | 1 |
| Yang, X | 1 |
| An, L | 1 |
| Gao, B | 1 |
| Liu, X | 1 |
| Liu, S | 1 |
| RajaSankar, S | 1 |
| Manivasagam, T | 1 |
| Sankar, V | 1 |
| Prakash, S | 1 |
| Muthusamy, R | 1 |
| Krishnamurti, A | 1 |
| Surendran, S | 1 |
| Kim, ST | 1 |
| Son, HJ | 1 |
| Choi, JH | 1 |
| Ji, IJ | 1 |
| Hwang, O | 1 |
| Lin, JW | 1 |
| Shih, CM | 1 |
| Chen, YC | 1 |
| Lin, CM | 1 |
| Tsai, JT | 1 |
| Chiang, YH | 1 |
| Shih, R | 1 |
| Chiu, PL | 1 |
| Hung, KS | 1 |
| Yeh, YS | 1 |
| Wei, L | 1 |
| Chiu, WT | 1 |
| Yang, LY | 1 |
| Yang, XX | 1 |
| Xue, SR | 1 |
| Dong, WL | 1 |
| Kong, Y | 1 |
| Reksidler, AB | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Barnabé, GF | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Vital, MA | 1 |
| Kuroiwa, H | 1 |
| Yokoyama, H | 2 |
| Kimoto, H | 2 |
| Kato, H | 5 |
| Araki, T | 5 |
| Borah, A | 1 |
| Mohanakumar, KP | 1 |
| Kurian, MA | 1 |
| Li, Y | 1 |
| Zhen, J | 1 |
| Meyer, E | 1 |
| Hai, N | 1 |
| Christen, HJ | 1 |
| Hoffmann, GF | 1 |
| Jardine, P | 1 |
| von Moers, A | 1 |
| Mordekar, SR | 1 |
| O'Callaghan, F | 1 |
| Wassmer, E | 1 |
| Wraige, E | 1 |
| Dietrich, C | 1 |
| Lewis, T | 1 |
| Hyland, K | 1 |
| Heales, S | 2 |
| Sanger, T | 1 |
| Gissen, P | 1 |
| Assmann, BE | 1 |
| Reith, ME | 1 |
| Maher, ER | 1 |
| Chao, OY | 2 |
| Huston, JP | 3 |
| von Bothmer, A | 1 |
| Pum, ME | 2 |
| Mattern, C | 1 |
| Silva, AM | 1 |
| Wessler, J | 1 |
| Ruocco, LA | 1 |
| Nikolaus, S | 1 |
| Baiguera, C | 1 |
| Alghisi, M | 1 |
| Pinna, A | 1 |
| Bellucci, A | 1 |
| De Luca, MA | 1 |
| Frau, L | 1 |
| Morelli, M | 1 |
| Ingrassia, R | 1 |
| Benarese, M | 1 |
| Porrini, V | 1 |
| Pellitteri, M | 1 |
| Bertini, G | 1 |
| Fabene, PF | 1 |
| Sigala, S | 1 |
| Spillantini, MG | 1 |
| Liou, HC | 1 |
| Spano, PF | 1 |
| Pizzi, M | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 1 |
| Manning-Bog, AB | 1 |
| Thiffault, C | 2 |
| Langston, JW | 2 |
| Cory-Slechta, DA | 1 |
| Di Monte, DA | 2 |
| Tillerson, JL | 2 |
| Cohen, AD | 1 |
| Caudle, WM | 2 |
| Zigmond, MJ | 1 |
| Schallert, T | 1 |
| Miller, GW | 2 |
| Breidert, T | 1 |
| Callebert, J | 1 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Launay, JM | 1 |
| Grondin, R | 1 |
| Zhang, Z | 1 |
| Yi, A | 1 |
| Cass, WA | 1 |
| Maswood, N | 1 |
| Andersen, AH | 1 |
| Elsberry, DD | 1 |
| Klein, MC | 1 |
| Gerhardt, GA | 1 |
| Gash, DM | 1 |
| Reverón, ME | 1 |
| Datla, KP | 1 |
| Murray, HE | 1 |
| Pillai, AV | 1 |
| Gillies, GE | 1 |
| Dexter, DT | 1 |
| Zafar, KS | 1 |
| Siddiqui, A | 1 |
| Sayeed, I | 1 |
| Ahmad, M | 1 |
| Salim, S | 1 |
| Islam, F | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 1 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Shimizu, K | 1 |
| Matsubara, K | 1 |
| Ohtaki, K | 1 |
| Fujimaru, S | 1 |
| Saito, O | 1 |
| Shiono, H | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Shimazu, S | 1 |
| Takahata, K | 1 |
| Tamashiro, A | 1 |
| Yoneda, F | 1 |
| Iida, Y | 1 |
| Saji, H | 1 |
| Crawley, F | 1 |
| Rudge, P | 1 |
| Diepold, K | 1 |
| Schütz, B | 1 |
| Rostasy, K | 1 |
| Wilken, B | 1 |
| Hougaard, P | 1 |
| Güttler, F | 1 |
| Romstad, A | 1 |
| Birk Møller, L | 1 |
| Oida, Y | 1 |
| Kitaichi, K | 1 |
| Nakayama, H | 1 |
| Ito, Y | 1 |
| Fujimoto, Y | 1 |
| Shimazawa, M | 1 |
| Nagai, H | 1 |
| Hara, H | 1 |
| Meuer, K | 1 |
| Pitzer, C | 1 |
| Teismann, P | 2 |
| Krüger, C | 1 |
| Göricke, B | 1 |
| Laage, R | 1 |
| Lingor, P | 1 |
| Peters, K | 1 |
| Schlachetzki, JC | 1 |
| Kobayashi, K | 1 |
| Dietz, GP | 1 |
| Weber, D | 1 |
| Schäbitz, WR | 1 |
| Bach, A | 1 |
| Schulz, JB | 2 |
| Bähr, M | 1 |
| Schneider, A | 1 |
| Weishaupt, JH | 1 |
| Ossowska, K | 1 |
| Smiałowska, M | 1 |
| Kuter, K | 1 |
| Wierońska, J | 1 |
| Zieba, B | 1 |
| Wardas, J | 1 |
| Dabrowska, J | 1 |
| Bortel, A | 1 |
| Biedka, I | 1 |
| Schulze, G | 1 |
| Rommelspacher, H | 1 |
| Bocharov, EV | 1 |
| Kucheryanu, VG | 1 |
| Kryzhanovskii, GN | 1 |
| Bocharova, OA | 1 |
| Belorustseva, SA | 1 |
| Megyeri, K | 1 |
| Marko, B | 1 |
| Sziray, N | 1 |
| Gacsalyi, I | 1 |
| Juranyi, Z | 1 |
| Levay, G | 1 |
| Harsing, LG | 1 |
| Liu, LX | 1 |
| Chen, WF | 1 |
| Xie, JX | 1 |
| Wong, MS | 1 |
| Takagi, S | 1 |
| Watanabe, Y | 1 |
| Kadoguchi, N | 1 |
| Yano, R | 1 |
| Nagamitsu, S | 1 |
| Matsuishi, T | 1 |
| Yamashita, Y | 1 |
| Yamada, S | 1 |
| Xue, YL | 1 |
| Wang, ZF | 1 |
| Zhong, DG | 1 |
| Cui, X | 1 |
| Li, XJ | 1 |
| Ma, XJ | 1 |
| Wang, LN | 1 |
| Zhu, K | 1 |
| Sun, AM | 1 |
| Hofele, K | 1 |
| Sedelis, M | 1 |
| Auburger, GW | 1 |
| Morgan, S | 1 |
| Schwarting, RK | 1 |
| Clarkson, ED | 1 |
| Zawada, WM | 1 |
| Bell, KP | 1 |
| Esplen, JE | 1 |
| Choi, PK | 1 |
| Heidenreich, KA | 1 |
| Freed, CR | 1 |
| Chekhonin, VP | 1 |
| Baklaushev, VP | 1 |
| Kogan, BM | 1 |
| Savchenko, EA | 1 |
| Lebedev, SV | 1 |
| Man'kovskaya, IV | 1 |
| Filatova, TS | 1 |
| Yusupova, IU | 1 |
| Dmitrieva, TB | 1 |
| Tariq, M | 1 |
| Khan, HA | 1 |
| Al Moutaery, K | 1 |
| Al Deeb, S | 1 |
| Bezard, E | 1 |
| Ravenscroft, P | 1 |
| Gross, CE | 1 |
| Crossman, AR | 1 |
| Meissner, W | 1 |
| Reum, T | 1 |
| Paul, G | 1 |
| Harnack, D | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Kupsch, A | 1 |
| Rathke-Hartlieb, S | 1 |
| Kahle, PJ | 1 |
| Neumann, M | 1 |
| Ozmen, L | 1 |
| Haid, S | 1 |
| Okochi, M | 1 |
| Haass, C | 1 |
| Muramatsu, Y | 1 |
| Tanaka, K | 2 |
| Matsubara, M | 2 |
| Imai, Y | 2 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Kumagai, T | 1 |
| Itoyama, Y | 1 |
| Collier, TJ | 1 |
| Sortwell, CE | 1 |
| Elsworth, JD | 1 |
| Taylor, JR | 1 |
| Roth, RH | 1 |
| Sladek, JR | 1 |
| Redmond, DE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Starving for Energy - A Pilot Study to Test Ketone Derived Energy in Eating Disorders[NCT05507008] | 40 participants (Anticipated) | Interventional | 2022-10-13 | Recruiting | |||
| Cerebral Autoregulation in Patients With Aneurysmal SubArachnoid Haemorrhage[NCT03987139] | 45 participants (Anticipated) | Interventional | 2019-06-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
64 other studies available for homovanillic acid and Parkinsonian Disorders
| Article | Year |
|---|---|
Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes.
Topics: Dopamine; Dopamine Plasma Membrane Transport Proteins; Homovanillic Acid; Humans; Parkinson Disease; | 2023 |
GPR55: A therapeutic target for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2017 |
Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Carnosine; Dopamine; Homovanillic Acid | 2018 |
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Corpus Striatum; Dopamine; Homova | 2013 |
The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzamides; Bridged Bicyclo Compounds; Calcium-Binding Prot | 2013 |
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpu | 2014 |
Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model.
Topics: Aluminum; Animals; Cell Line; Cell Survival; Homovanillic Acid; Hydroxides; Levodopa; Nanocomposites | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Amphetamine; Animals; Benzazepines; Central Nervous | 2016 |
The Incidence and Evolution of Parkinsonian Rigidity in Rett Syndrome: A Pilot Study.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Homovanillic Acid; Humans; Indoles; Male; Methyl | 2016 |
AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Animals; Corpus Striatum; Dependovirus; Dopamine; Dopamine | 2017 |
Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorocebus aethiops; Corpus Striatum; Di | 2008 |
MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2009 |
Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Brain; Brain Chemistry; Chromatography, | 2009 |
Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Glutathione; Glutathione | 2009 |
Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Chromatography, High | 2010 |
Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.
Topics: Animals; Biomarkers; Cell Count; Cell Death; Disease Models, Animal; Dopamine; Homovanillic Acid; Hy | 2009 |
Therapeutic effect of human amniotic epithelial cell transplantation into the lateral ventricle of hemiparkinsonian rats.
Topics: Amnion; Animals; Apomorphine; Chromatography, High Pressure Liquid; Epithelial Cells; Female; Homova | 2009 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2009 |
Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; C | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2010 |
Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.
Topics: Brain; Cell Line, Transformed; Child; Child, Preschool; Cohort Studies; Dopamine Plasma Membrane Tra | 2011 |
Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Res | 2011 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Anima | 2012 |
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice.
Topics: Aging; alpha-Synuclein; Animals; Cell Count; Corpus Striatum; Dopamine; Dopaminergic Neurons; Homova | 2012 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Drug Administra | 2002 |
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiparkinson Agents; Behavior, Animal; Corpus | 2002 |
Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorides; Diestrus; Dopamine; Dopamine Plasma Membrane Tra | 2003 |
Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Ascorbic Acid; Behavior, Animal; Brain; Disea | 2003 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug I | 2003 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Pl | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; | 2003 |
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2003 |
Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency.
Topics: Adult; Biopterins; Brain; Brain Diseases, Metabolic; Electroencephalography; Epilepsy; Female; Heroi | 2004 |
Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections.
Topics: Animals; Antiparkinson Agents; Central Nervous System Viral Diseases; Child, Preschool; DNA Mutation | 2005 |
Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2006 |
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Nor | 2006 |
Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cerebral Cortex; Chromatography, High Pre | 2006 |
Effect of complex phytoadaptogen on MPTP-induced Parkinson's syndrome in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopa | 2006 |
Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzodiazepines; Corpus Striatum; Dop | 2007 |
Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotectio | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Extrapontine myelinolysis with parkinsonism after rapid correction of hyponatremia: high cerebrospinal fluid level of homovanillic acid and successful dopaminergic treatment.
Topics: Antiparkinson Agents; Basal Ganglia; Child; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1999 |
Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Medulla; Animals; Antiparkinson Agents; Apomorphine; Capsule | 2000 |
Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2001 |
IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands.
Topics: Abortion, Induced; Animals; Apomorphine; Brain; Brain Tissue Transplantation; Cell Survival; Cells, | 2001 |
Catecholamines and their metabolites in the brain and urine of rats with experimental Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catecholamines; Dihydroxyphenylalanine; Dopamine; Ep | 2000 |
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents, Non- | 2001 |
Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Dopamine; Enzyme Inhibitors; Glutathione; | 2001 |
Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Enkephalins; Female; Gene Expression Regulation; | 2001 |
Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Electric Stimulation Therapy; Extracellular Space | 2001 |
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino | 2001 |
Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; D | 2001 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do | 2001 |
Neuroprotective effect of riluzole in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dizocilpine M | 2001 |
Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
Topics: Animals; Axons; Brain Tissue Transplantation; Cell Differentiation; Chlorocebus aethiops; Dopamine; | 2002 |